Publications by authors named "W Graybill"

Claim this Profile
P
Potential Synergistic Effect between Niraparib and Statins in Ovarian Cancer Clinical Trials.
Hailei Zhang, Anna Rutkowska, Antonio González-Martín, Mansoor R Mirza, Bradley J Monk, Whitney A Spannuth Graybill

Cancer Res Commun· January 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
U
Use of individualized starting dose and niraparib hematologic adverse event management costs in ovarian cancer.
Whitney S Graybill, Ignace Vergote, Bhavana Pothuri, Maarit Anttila, David M O'Malley

J Comp Eff Res· January 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Niraparib first-line maintenance therapy in patients with newly diagnosed advanced ovarian cancer: final overall survival results from the PRIMA/ENGOT-OV26/GOG-3012 trial.
B J Monk, M P Barretina-Ginesta, B Pothuri, I Vergote, W Graybill

Ann Oncol· November 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Patterns of initial ovarian cancer recurrence on niraparib maintenance monotherapy in patients with no baseline evidence of disease after first-line chemotherapy: An ad hoc subgroup analysis of PRIMA/ENGOT-OV26/GOG-3012.
Mitchell R Kamrava, Antonio Gonzalez-Martin, Bhavana Pothuri, Ignace Vergote, Whitney Graybill

Gynecol Oncol· October 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Niraparib Population Pharmacokinetics and Exposure-Response Relationships in Patients With Newly Diagnosed Advanced Ovarian Cancer.
Bradley J Monk, Ignacio Romero, Whitney Graybill, Cristina Churruca, David M O'Malley

Clin Ther· August 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis